CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. (CBAY) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · CBAY · as of Jun 9, 2026
Activity summary
Buy transactions
1
P-Purchase only
Sell transactions
48
12 Months
Buy/Sell ratio
0.02
Buy/Sell (by trades)
Overall sentiment
CymaBay Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
CBAY insider buying and selling by quarter
CBAY insider selling · CBAY insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Recent insider transactions
CBAY executive sell shares · CBAY board member insider trading · CBAY insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Mar 22, 2024 | McWherter Charles President of R&D | Other | 31,938 | $1.04M⚡ | Form 4 |
| Mar 22, 2024 | Shantharam Harish CFO | Other | 20,125 | $654K | Form 4 |
| Mar 22, 2024 | Dickinson Klara Chief Regulatory Officer | Other | 21,000 | $683K | Form 4 |
| Mar 22, 2024 | Quinlan Paul T General Counsel | Other | 28,438 | $924K | Form 4 |
| Mar 22, 2024 | Wills Robert James Director | Other | 30,000 | $975K | Form 4 |
| Mar 22, 2024 | Shah Sujal CEO · Director | Other | 96,250 | $3.13M⚡ | Form 4 |
| Mar 22, 2024 | EMSTER KURT VON Director | Other | 90,000 | $2.92M⚡ | Form 4 |
| Mar 13, 2024 | Shah Sujal CEO · Director | Option | 1 | $3 | Form 4 |
| Mar 13, 2024 | Shah Sujal CEO · Director | Option | 2,288 | $13K | Form 4 |
| Mar 13, 2024 | Shah Sujal CEO · Director | Option | 22,076 | $89K | Form 4 |
| Mar 13, 2024 | Shah Sujal CEO · Director | Option | 14,372 | $121K | Form 4 |
| Mar 13, 2024 | Shah Sujal CEO · Director | Option | 3,125 | $37K | Form 4 |
| Mar 13, 2024 | Shah Sujal CEO · Director | Option | 18,899 | $174K | Form 4 |
| Mar 13, 2024 | Shah Sujal CEO · Director | Option | 52,084 | $90K | Form 4 |
| Mar 13, 2024 | Shah Sujal CEO · Director | Option | 14,625 | $16K | Form 4 |
McWherter Charles
President of R&D
Date
Mar 22
Shares
31,938
Price
$32.50
Value
$1.04M ⚡
Dickinson Klara
Chief Regulatory Officer
Date
Mar 22
Shares
21,000
Price
$32.50
Value
$683K
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About CBAY insider trading
CBAY insider trades
CymaBay Therapeutics, Inc. (CBAY) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including CBAY. Over the past 12 months, 0 insiders have filed transactions with the SEC. CBAY insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For CymaBay Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
CBAY insider trading · 5 questionsThe insiders of CymaBay Therapeutics, Inc. (CBAY) include executives and directors such as CBAY, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026